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Background: There is a lack of objective measures of the clinical efficacy of allergen immunotherapy which relies
on patients’ perception about the effect of this treatment. We studied whether the fraction of exhaled nitric oxide
is affected by multiple allergen immunotherapy in polysensitized adult subjects with allergic rhinitis. We also looked
for associations between exhaled nitric oxide and subjects’ demographics, symptom scores, and pulmonary
function tests.
Methods: Twenty adult, polysensitized subjects with seasonal and perennial allergic rhinitis who chose to undergo
allergen immunotherapy were enrolled. They were evaluated at baseline, and 4, 8, 12, 24, and 52 weeks later.
Exhaled nitric oxide was reported as the mean of triplicate determinations.
Findings: Our results indicate that multiple allergen immunotherapy did not affect exhaled nitric oxide levels and
such levels did not correlate with subjects’ demographics and pulmonary function tests. However, exhaled nitric
oxide was associated with rhinoconjuctivitis and asthma symptom scores at the end of the study.
Conclusions: In polysensitized adult subjects with allergic rhinitis, exhaled nitric oxide levels are unaffected by
multiple allergen immunotherapy.
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Background
The fraction of exhaled nitric oxide (FENO) is elevated
in subjects with allergic rhinitis compared to healthy
controls, although less than in asthmatics [1]. Increased
FENO levels have been proposed as indicative of eosino-
philic airway inflammation and FENO is typically re-
duced by steroids, drugs known to decrease such
inflammation [2]. It could be hypothesized that FENO
levels could be used as an objective measure of the se-
verity of allergic rhinitis.
Treatment of asthmatic children and adults with a
monoclonal humanized anti-IgE antibody, omalizumab
(Xolair) decreased FENO levels [3,4] and elevated
FENO levels can help predicting the response to this
treatment [5]. In contrast, conventional single allergen
immunotherapy (IT) in mostly polysensitized asthmatic
children and adults did not significantly affect FENO* Correspondence: michelecolumbo@msn.com
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reproduction in any medium, provided the or[6,7]. To our knowledge, there is no information
concerning the effect of multiple allergen IT on FENO.
Also as there is a lack of objective parameters to assess
the efficacy of IT, we postulated that multiple allergen
IT may modulate FENO levels in adult patients. Mul-
tiple allergen IT is routinely employed in the USA to
treat polysensitized individuals with allergic rhinitis and
asthma. FENO is positively associated with the number
of positive skin tests in children with asthma and aller-
gic rhinitis [8]. We examined associations among FENO
and subjects’ demographics and the number of positive
skin tests. As subjects with asthma were allowed to par-
ticipate, we addressed associations among FENO and
Asthma Control Test (ACT) scores and spirometric
measurements.Methods
Twenty adult subjects just diagnosed with allergic rhin-
itis who elected to begin IT in an Allergy and Immun-
ology practice in suburban Philadelphia were recruited
and enrolled in the study. Prick tests were performedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Subjects’ Characteristics at Baseline
Female/Male 13/7
Age, yr (range) 36.3 ± 12.8 (21–71)





Number of positive allergy tests (range) 10.4 ± 7.3 (2–25)
Asthma 9/20
ARCS Score 6.3 ± 3.8
ACT Score 23 ± 4.1
FENO (ppb) (range) 32.4 ± 19.8 (8–88)
FEV1 (%) 101.7 ± 12.2
FEV1/FVC 0.79 ± 0.07
FEF25-75% 90.8 ± 24.2
Some results are expressed as the mean ± S.D. N = 20.
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and outdoor allergens (Greer, Lenoir, NC). Current or
past smokers were excluded. This study was approved
by the Main Line Hospitals Institutional Review Board
and registered on ClinicalTrials.gov (NCT01318954).
The study subjects were followed for one year with
evaluations including a brief history, physical exam, collec-
tion of ACT and reflective Allergic RhinoConjunctivitis
Symptoms (ARCS) scores at baseline and at 4, 8, 12, 24
and 52 weeks. Allergic RhinoConjunctivitis Symptoms
(ARCS) score is a scoring system for five groups of symp-
toms: 1) sneezing, 2) rhinorrhea (postnasal drip), 3) itchy
nose/palate/throat, 4) itchy/watery or red eyes, and 5)
nasal congestion. The study subjects were instructed to
grade each of the five symptoms they were experiencing
at the time of the visit on a scale including 0 (no symp-
tom), 1 (mild), 2 (moderate), 3 (severe), 4 (very severe).
The Asthma Control Test (ACT) is a commonly used
tool that allows patients to grade their asthmatic symp-
toms. Patients report on a scale from 1 (severe) to 5 (no
symptoms) their asthmatic symptoms in the previous
four weeks by answering five questions about their
asthma. Values over 19 are considered as indicative of
good asthma control. Three subjects discontinued the
IT within three months and were not included in the
analysis. Seventeen subjects completed the study.
Allergy vaccines were prepared according to the
subjects’ sensitivities, using purified extracts (Greer,
Lenoir, NC; Hollister Stier, Spokane, WA; ALK Abello’,
Port Washington, NY), and an initial dose equivalent
to 1:500 of the maintenance dose. Such maintenance
doses of the individual allergens were within the range
of the published guidelines. The injections were given
weekly while the vaccine’s dose was increased and ad-
ministered every four weeks as maintenance. The IT
was administered as two injections, containing peren-
nial and pollen allergens, respectively. If scheduled for
the same day, the allergy injections were administered
after the study visit. All of the subjects who completed
the study suffered from both perennial and seasonal
allergic rhinitis. The most common sensitivities were
dust mite (80%), ragweed (70%), and cat (65%). Sub-
jects’ compliance with the IT schedule was excellent.
In particular, >90% of the injections were given in
seven days (± 2 days) during the dose escalation phase
and in 28 days (± 7 days) during the maintenance
phase of the IT.
Spirometric values were obtained according to the
ATS/ERS guidelines by a KoKo Spirometer (nSpire
Health, Inc, Longmont, Colorado). FENO was mea-
sured in triplicate determinations by NIOX MINO
(Aerocrine, Morrisville, NC) according to the ATS/ERS
guidelines and reported as ppb as the mean of the three
determinations.Statistical analysis was performed using STATA v10
(College Station, TX). Descriptive variables are expressed
as means and standard deviation, Multiple linear regres-
sion was used to test association between groups of vari-
ables and group differences were tested using unpaired
t-tests. Significance was accepted at alpha = .05 with no
adjustment for multiple comparisons.
Results
Table 1 summarizes the subjects’ characteristics at base-
line. If only the subjects who completed the study were
reported, the data were essentially unchanged. Eight sub-
jects had mild intermittent and one had mild persistent
asthma.
There were no significant differences between the
values of FENO at consecutive study visits in all study
subjects. Similarly, there was no significant difference in
FENO values between the first and the last visits (33.5 ±
19.5 vs. 40.5 ± 27.5 ppb, respectively, p = 0.4). In the
asthmatics, FENO showed a trend for an increase after
IT (40.1 ± 19.9 ppb at baseline vs. 50.6 ± 29.9 ppb at the
last visit, n = 9), but this was not statistically significant
(p = 0.4). This was similar in the subjects without asthma
(26 ± 17.1 vs. 28.9 ± 20.2, respectively, p = 0.76, n = 8).
The reflective ARCS scores were only collected at the
six study visits in subjects with multiple allergic sensitiv-
ities. The subjects’ starting date of IT was not synchro-
nized with their pollen season. Therefore, such scores
could not be used to assess the clinical efficacy of IT.
However, they slightly increased up to the third visit
(from 6.4 ± 4.1 to 7.4 ± 4.8) and then progressively
decreased in the subsequent visits until the last study
visit (to 4.9 ± 4). Whereas the ARCS scores did not vary
significantly between first and last study visit (p = 0.16),
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third visit (p = 0.03). ACT scores and pulmonary func-
tion tests, both high at baseline, did not vary signi-
ficantly throughout the study period and were similar
in asthmatic and non-asthmatic subjects (data not
shown). The effect of IT on the utilization of drugs
could not be reliably assessed because of the low use at
baseline.
We found no association between FENO and number
of positive skin tests (p = 0.9), or age, sex, and Body
Mass Index (BMI) (p > 0.14). FENO was higher in sub-
jects with asthma (40.1 ± 19.9 vs. 26 ± 17.1 ppb), but this
did not reach statistical significance (p = 0.09) likely due
to the small number of observations. Similarly, we found
no association among FENO and FEV1, FEV1/FVC, or
FEF25-75% at baseline and at the end of the study. At the
final study visit, FENO was positively associated with
ARCS scores and negatively correlated with ACT scores
(p = 0.01 for both). Eighty eight percent of the subjects
who completed the study judged the IT clinically effect-
ive. This conclusion was based on the subjective, yet sig-
nificant reduction of their rhinoconjunctivitis symptoms
over the year of treatment when compared to their
symptoms’ severity in the previous years.
Discussion
FENO was elevated (>30 ppb) in our study subjects but
it was unaffected by multiple allergen IT. Similar results
were obtained when only asthmatic subjects were in-
cluded in the analysis.
Unlike studies in children, FENO was not associated
with the number of positive skin tests. As in other
studies [9], FENO was not associated with age, sex, or
BMI in our study subjects. Although we did not find an
association with asthma, it is likely that a larger num-
ber of observations would have resulted in a positive
association.
Similar to other studies [10], including ours of FENO in
elderly asthmatics [11], we found no association between
FENO and FEV1, FEV1/FVC, or FEF25-75% throughout the
study period.
FENO was not associated with ARCS and ACT scores
at baseline and throughout most of the study period.
However, at the end of the study, we found a significant
positive association between FENO and ARCS and a
negative association between FENO and ACT scores.
The reasons for these correlations are unclear. Such
findings may have occurred by chance. However, we
speculate that IT, while not leading to significant varia-
tions in FENO levels, may induce biologic changes that
cause such associations.
Limitations of our study include the small sample size
which limits the study’s ability to detect small changes
in FENO if the FENO measurements are relativelyunresponsive to change. The small sample size could
have also prevented us from observing weaker associa-
tions between the different parameters. In addition, as it
is routinely done in clinical practice, the efficacy of IT
was subjectively established by the study participants.
Conclusion
In conclusion, in our pilot study FENO levels were un-
affected in subjects undergoing multiple allergen IT. The
results of our study will require confirmation in larger
subject cohorts.
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